Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276

RecruitingPhase 3

Sponsor: Bristol-Myers Squibb

Conditions: Extensive-Stage Small Cell Lung Cancer

Interventions: BMS-986489 (BMS-986012+Nivolumab), Atezolizumab, Carboplatin, Etoposide

Countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria

* Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
* Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
* Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system

Exclusion Criteria

* Participants have already received certain types of treatment for extensive stage small cell lung cancer
* Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy
* Other protocol-defined Inclusion/Exclusion criteria apply.
Locations (183)
  • Daphne, Alabama, United States
  • Hot Springs, Arkansas, United States
  • Fort Myers, Florida, United States
  • Orange City, Florida, United States
  • St. Petersburg, Florida, United States
  • Marietta, Georgia, United States
  • Peoria, Illinois, United States
  • Minneapolis, Minnesota, United States
  • Albuquerque, New Mexico, United States
  • Durham, North Carolina, United States
  • Bismarck, North Dakota, United States
  • Fargo, North Dakota, United States
  • Cincinnati, Ohio, United States
  • Sioux Falls, South Dakota, United States
  • Nashville, Tennessee, United States
  • Austin, Texas, United States
  • Tyler, Texas, United States
  • Roanoke, Virginia, United States
  • Edmonds, Washington, United States
  • Seattle, Washington, United States
  • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • ABB, Buenos Aires F.D., Argentina
  • Buenos Aires, Buenos Aires F.D., Argentina
  • CABA, Buenos Aires F.D., Argentina
  • Río Cuarto, Córdoba Province, Argentina
  • Campbelltown, New South Wales, Australia
  • Penrith, New South Wales, Australia
  • Brisbane, Queensland, Australia
  • Ballarat Central, Victoria, Australia
  • Murdoch, Western Australia, Australia
  • + 153 more on CT.gov